InvestSMART

Telix Pharmaceuticals Limited (ASX: TLX) - Announcements

Current share price for TLX : $14.500 0.03 (0.21%)+

ASX company news and announcements for Telix Pharmaceuticals Limited (TLX) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Telix Pharmaceuticals Limited (TLX) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Telix Pharmaceuticals Limited (TLX), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Telix Pharmaceuticals Limited (TLX)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$4,927 Pending Release of Shares from Voluntary Escrow 23 Oct 2024 8:22AM $21.020 $14.500 fallen by 31.02%
$4,927 Telix Files Form 20-F Registration Statement for Nasdaq ADS 18 Oct 2024 8:21AM $21.000 $14.500 fallen by 30.95%
$4,927 Appendix 3Z Final Director Notice (A Kluge) 17 Oct 2024 5:10PM $21.000 $14.500 fallen by 30.95%
$4,927 Andreas Kluge to Retire from Telix Board 17 Oct 2024 5:10PM $21.000 $14.500 fallen by 30.95%
$4,927 Telix Q3 2024 Revenue and Business Update 17 Oct 2024 5:08PM $21.000 $14.500 fallen by 30.95%
$4,927 Notification of cessation of securities - TLX 8 Oct 2024 8:26AM $20.490 $14.500 fallen by 29.23%
$4,927 Application for quotation of securities - TLX 8 Oct 2024 8:25AM $20.490 $14.500 fallen by 29.23%
$4,927 Application for quotation of securities - TLX 26 Sep 2024 8:25AM $20.120 $14.500 fallen by 27.93%
$4,927 Telix to Acquire RLS for US Manufacturing and Distribution 23 Sep 2024 8:25AM $20.310 $14.500 fallen by 28.61%
$4,927 Notification regarding unquoted securities - TLX 11 Sep 2024 8:21AM $18.150 $14.500 fallen by 20.11%
$4,927 Application for quotation of securities - TLX 9 Sep 2024 8:26AM $17.740 $14.500 fallen by 18.26%
$4,927 Becoming a substantial holder 30 Aug 2024 6:35PM $18.610 $14.500 fallen by 22.08%
$4,927 Telix Submits NDA for TLX101-CDx Brain Cancer Imaging Agent 28 Aug 2024 8:17AM $19.970 $14.500 fallen by 27.39%
$4,927 Telix Reorganisation to Deliver on Strategic Priorities 27 Aug 2024 8:08AM $19.860 $14.500 fallen by 26.99%
$4,927 Ceasing to be a substantial holder 22 Aug 2024 6:10PM $19.780 $14.500 fallen by 26.69%
$4,927 Securities Dealing Policy - Updated 22 Aug 2024 5:23PM $19.780 $14.500 fallen by 26.69%
$4,927 Telix 1H 2024 Results Presentation 22 Aug 2024 4:42PM $19.780 $14.500 fallen by 26.69%
$4,927 Telix 1H 2024 Results Release 22 Aug 2024 4:41PM $19.780 $14.500 fallen by 26.69%
$4,927 Telix 1H 2024 Appendix 4D and Interim Report 22 Aug 2024 4:40PM $19.780 $14.500 fallen by 26.69%
$4,927 Becoming a substantial holder 21 Aug 2024 6:07PM $19.970 $14.500 fallen by 27.39%
$4,927 Ceasing to be a substantial holder 14 Aug 2024 2:47PM $18.490 $14.500 fallen by 21.58%
$4,927 Telix 2024 Half-Year Results Investor Webcast Notification 13 Aug 2024 8:15AM $17.990 $14.500 fallen by 19.40%
$4,927 Becoming a substantial holder 13 Aug 2024 8:10AM $17.990 $14.500 fallen by 19.40%
$4,927 Ceasing to be a substantial holder 7 Aug 2024 5:38PM $17.720 $14.500 fallen by 18.17%
$4,927 Ceasing to be a substantial holder 5 Aug 2024 8:15AM $18.850 $14.500 fallen by 23.08%

226 - 250 of 947 results

Page 10 of 38

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.